Director

Christopher Simms

Chief Commercial and Business Officer·4D Molecular Therapeutics, Inc.

About

Christopher Simms has served as 4DMT's Chief Commercial and Business Officer since December 2025, and served as Chief Commercial Officer from September 2024 until December 2025.

Mr. Simms previously served as Chief Commercial Officer at IVERIC bio, Inc. from August 2021 to July 2024. From November 2017 to July 2021, he served in various roles at Novartis AG, most recently as VP, Head of US Ophthalmics.

Mr. Simms holds an MBA degree from York University, Schulich School of Business, and a Bachelor of Commerce from Memorial University of Newfoundland.

Since 2024
Age 51
Tenure 2 yrs

Also at 4D Molecular Therapeutics, Inc.

DM David Kirn, M.D. Co-Founder, President, Chief Executive Officer and Director JP John F. Milligan, Ph.D. Director and Executive Chairman JM Jacob Chacko, M.D., MBA Director SM Susannah Gray, MBA Director CP Charles P. Theuer, M.D., Ph.D. Director NM Nancy Miller-Rich Director

Roles

Organization Role Dates Details
4D Molecular Therapeutics, Inc. Chief Commercial and Business Officer 2024–present Current role
IVERIC bio, Inc. Chief Commercial Officer 2021-2024 Chief Commercial Officer from August 2021 to July 2024.
Novartis AG VP, Head of US Ophthalmics 2017-2021 Various roles from November 2017 to July 2021, most recently VP, Head of US Ophthalmics.

Related

Company 4D Molecular Therapeutics, Inc. Company hub Person David Kirn, M.D. Co-Founder, President, Chief Executive Officer and Director Person John F. Milligan, Ph.D. Director and Executive Chairman Person Jacob Chacko, M.D., MBA Director Person Susannah Gray, MBA Director Person Charles P. Theuer, M.D., Ph.D. Director Person Nancy Miller-Rich Director Person Shawn Cline Tomasello, MBA Director Person Glenn Sblendorio Director Person Kristian Humer Chief Financial Officer Person Scott Bizily, J.D., Ph.D. Chief Legal Officer and Corporate Secretary Person Ashoo Gupta Vice President, Finance and Controller Person Fariborz Kamal, Ph.D. Former President and Chief Operating Officer; Chief Technical Advisor
Source: 4D Molecular Therapeutics, Inc. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo